NY-IFF
IFF (NYSE:IFF) has released its 2021 environmental, social and governance plus sustainable solutions (or ESG+) performance report. Published today, “Transforming Our World ,” details the Company’s commitment to do more good for people and the planet, aligned with IFF’s purpose—Applying science and creativity for a better world. Centered around the recently launched Do More Good Plan , the report updates progress on legacy IFF targets, looks ahead to even more ambitious 2030 objectives, and aims to address the world’s most pressing sustainable development challenges from IFF’s perspective.
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET.
“At IFF, we’re taking a holistic approach to creating a better world by leveraging our business, performance and partners,” said Frank Clyburn, IFF CEO. “Since the launch of our first sustainability program in 2010, we’ve made tremendous progress. To continue driving results, we’re challenging our teams to be accountable, to collaborate across divisions, and to execute on our ESG+ strategy.”
“At today’s IFF, we’re taking another bold step, embedding a more comprehensive ESG structure in every part of our business, including the solutions we produce to help our customers reach their own ESG goals,” Mr. Clyburn continued. “Following the merger with DuPont’s Nutrition and Biosciences division, this report showcases our first year of results since launching our Do More Good Plan. We’re proud of the many ways we’re becoming a stronger, more resilient company, as we apply science and creativity for a better world.”
The 2021 ESG+ Report aligns with the Do More Good Plan’s four pillars: Sustainable Solutions, Climate and Planetary Health, Equity and Wellbeing, and Transparency & Accountability.
Examples of 2021 performance highlights and achievements include:
- Recognized for ESG leadership: named to the Dow Jones Sustainability Indices for the second consecutive year, received the EcoVadis platinum sustainability rating, and included in the Bloomberg Gender Equality Index
- Enabled and accelerated the wider adoption of sustainable solutions in the marketplace across divisions, and promoted circular economy growth through IFF products verified as Upcycled Certified™
- Continued commitment to climate action—being one of only 14 companies out of nearly 12,000 assessed—named by CDP as a triple A list company for corporate transparency on climate change, water stewardship and deforestation
- Strengthened commitment to diversity, equity and inclusion, honored by the Human Rights Campaign as a Best Place to Work for LGBTQ Equality for the third consecutive year, and named among the Best Places to Work for Disability Inclusion by Disability:IN for the second consecutive year
To read IFF’s 2021 ESG+ Report, click here or visit: https://www.iff.com/responsibilities/strategy-reporting/report-library .
Webcast
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ metrics and performance results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET. Mr. Clyburn will be joined by Michael DeVeau, Chief Investor Relations & Communications Officer; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Pete Sommers, Interim Chief Human Resources and Diversity, Equity & Inclusion Officer; and Kip Cleverley, Vice President, Global Sustainability & EHS. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .
Investors and analysts are invited to participate by phone by calling 866-342-8591 from the United States and 203-518-9713 from other locations. The access code for the conference call is IFF0609. A live listen-only webcast will also be available at ir.iff.com . For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF)—an industry leader in food, beverage, scent, health and biosciences—science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom